These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
154 related items for PubMed ID: 8615167
1. Striatal dopamine D2 receptor alterations and response to L-DOPA in Parkinson's disease. A [123I]IBZM SPET study. Pizzolato G, Cagnin A, Rossato A, Chierichetti F, Fabbri M, Dam M, Ferlin G, Battistin L. Adv Neurol; 1996; 69():467-73. PubMed ID: 8615167 [No Abstract] [Full Text] [Related]
2. Alterations of striatal dopamine D2 receptors contribute to deteriorated response to L-dopa in Parkinson's disease: a [123I]-IBZM SPET study. Pizzolato G, Chierichetti F, Rossato A, Cagnin A, Fabbri M, Dam M, Ferlin G, Battistin L. J Neural Transm Suppl; 1995; 45():113-22. PubMed ID: 8748616 [Abstract] [Full Text] [Related]
3. [The determination of cerebral dopamine (D2) receptor density by using 123I-IBZM-SPECT in Parkinson disease patients]. Hierholzer J, Cordes M, Schelosky L, Barzen G, Poewe W, Henkes H, Keske U, Horowski R, Felix R. Rofo; 1992 Oct; 157(4):390-8. PubMed ID: 1391843 [Abstract] [Full Text] [Related]
4. Iodine-123-iodobenzamide binding in parkinsonism: reduction by dopamine agonists but not L-Dopa. Schwarz J, Oertel WH, Tatsch K. J Nucl Med; 1996 Jul; 37(7):1112-5. PubMed ID: 8965179 [Abstract] [Full Text] [Related]
5. Do dopamine agonists or levodopa modify Parkinson's disease progression? Marek K, Jennings D, Seibyl J. Eur J Neurol; 2002 Nov; 9 Suppl 3():15-22. PubMed ID: 12464117 [Abstract] [Full Text] [Related]
6. L-Dopa-responsive Parkinson's syndrome in association with phenylketonuria: In vivo dopamine transporter and D2 receptor findings. Evans AH, Costa DC, Gacinovic S, Katzenschlager R, O'sullivan JD, Heales S, Lee P, Lees AJ. Mov Disord; 2004 Oct; 19(10):1232-6. PubMed ID: 15390012 [Abstract] [Full Text] [Related]
7. [Dopamine (D2) receptor SPECT with 123I-iodobenzamide (IBZM) in diagnosis of Parkinson syndrome]. Reiche W, Grundmann M, Huber G. Radiologe; 1995 Nov; 35(11):838-43. PubMed ID: 8657887 [Abstract] [Full Text] [Related]
8. Dopamine receptor SPET imaging in Parkinson's disease: a [123I]-IBZM and [99mTc]-HM-PAO study. Pizzolato G, Chierichetti F, Rossato A, Briani C, Dam M, Borsato N, Saitta B, Zanco P, Ferlin G, Battistin L. Eur Neurol; 1993 Nov; 33(2):143-8. PubMed ID: 8467821 [Abstract] [Full Text] [Related]
9. Sustained striatal dopamine levels following intestinal levodopa infusions in Parkinson's disease patients. Politis M, Sauerbier A, Loane C, Pavese N, Martin A, Corcoran B, Brooks DJ, Ray-Chaudhuri K, Piccini P. Mov Disord; 2017 Feb; 32(2):235-240. PubMed ID: 27859651 [Abstract] [Full Text] [Related]
10. Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders. Brücke T, Podreka I, Angelberger P, Wenger S, Topitz A, Küfferle B, Müller C, Deecke L. J Cereb Blood Flow Metab; 1991 Mar; 11(2):220-8. PubMed ID: 1671782 [Abstract] [Full Text] [Related]
11. Downregulation of striatal dopamine D2 receptors in advanced Parkinson's disease contributes to the development of motor fluctuation. Hwang WJ, Yao WJ, Wey SP, Shen LH, Ting G. Eur Neurol; 2002 Mar; 47(2):113-7. PubMed ID: 11844900 [Abstract] [Full Text] [Related]
12. [123]IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy. Schwarz J, Tatsch K, Gasser T, Arnold G, Oertel WH. Mov Disord; 1997 Nov; 12(6):898-902. PubMed ID: 9399212 [Abstract] [Full Text] [Related]
13. Modification of dopamine D2 receptor activity by pergolide in Parkinson's disease: an in vivo study by PET. Linazasoro G, Obeso JA, Gómez JC, Martínez M, Antonini A, Leenders KL. Clin Neuropharmacol; 1999 Nov; 22(5):277-80. PubMed ID: 10516878 [Abstract] [Full Text] [Related]
14. IBZM-SPECT imaging in Parkinson's disease. Quantification of binding ratios from sequential SPECT measurements in patients and controls. Cordes M, Hierholzer J, Schelosky L, Poewe W, Cordes I, Horowski R, Eichstaedt H, Schmidt D, Felix R. Adv Neurol; 1993 Nov; 60():525-8. PubMed ID: 8420183 [No Abstract] [Full Text] [Related]
15. 123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism. Schwarz J, Tatsch K, Gasser T, Arnold G, Pogarell O, Künig G, Oertel WH. Mov Disord; 1998 Jan; 13(1):16-9. PubMed ID: 9452320 [Abstract] [Full Text] [Related]
16. Quantification of IBZM dopamine receptor SPET in de novo Parkinson patients before and during therapy. Hertel A, Weppner M, Baas H, Schreiner M, Maul FD, Baum RP, Fischer PA, Hör G. Nucl Med Commun; 1997 Sep; 18(9):811-22. PubMed ID: 9352546 [Abstract] [Full Text] [Related]
17. 123I-iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism. Schwarz J, Tatsch K, Arnold G, Gasser T, Trenkwalder C, Kirsch CM, Oertel WH. Neurology; 1992 Mar; 42(3 Pt 1):556-61. PubMed ID: 1549216 [Abstract] [Full Text] [Related]
18. Lateralized differences in iodine-123-IBZM uptake in the basal ganglia in asymmetric Parkinson's disease. Knable MB, Jones DW, Coppola R, Hyde TM, Lee KS, Gorey J, Weinberger DR. J Nucl Med; 1995 Jul; 36(7):1216-25. PubMed ID: 7790947 [Abstract] [Full Text] [Related]
19. Levodopa for Parkinson's disease. Gérard JM, Elosegi JA. N Engl J Med; 2009 Feb 26; 360(9):936; author reply 936. PubMed ID: 19256032 [No Abstract] [Full Text] [Related]
20. Single photon emission computed tomography striatal asymmetry index may predict dopaminergic responsiveness in Parkinson disease. Contrafatto D, Mostile G, Nicoletti A, Raciti L, Luca A, Dibilio V, Lanzafame S, Distefano A, Drago F, Zappia M. Clin Neuropharmacol; 2011 Feb 26; 34(2):71-3. PubMed ID: 21406999 [Abstract] [Full Text] [Related] Page: [Next] [New Search]